In a retrospective study of PS 2 NSCLC patients with PD-L1 TPS ≥ 50% receiving first-line pembrolizumab monotherapy, prognosis differed, depending on whether the reason for poor PS was due to cachectic factors or complications (11). This evidence concerns the gene CD274 and non-small cell lung carcinoma.